Syngene Delivers Steady Growth in Q4 FY25; Full-Year PAT Down 8%
ECONOMY & POLICY

Syngene Delivers Steady Growth in Q4 FY25; Full-Year PAT Down 8%

Syngene International reported a strong performance in Q4 FY25 with revenue from operations rising 11% year-on-year to Rs 10.18 billion, crossing the Rs 10 billion mark for the first time. The quarter also saw sequential revenue growth of 8%, supported by robust performance across research, development, and manufacturing services. Operating EBITDA grew 9% YoY, with a margin of 35%, while profit after tax stood at Rs 1.83 billion. 

For the full fiscal year, revenue from operations rose 4% to Rs 36.42 billion. However, profit after tax before exceptional items declined 8% to Rs 4.75 billion, impacted by sectoral headwinds in the first half. Adjusted for one-offs, full-year PAT remained flat with 1% YoY growth. EBITDA margin for the year moderated to 29%. 

Key highlights included the acquisition of a biologics manufacturing site in Baltimore, USA, enhancing Syngene’s single-use bioreactor capacity to 50KL and expanding its footprint in the US biologics CDMO market. The company also launched SYNe-MAP™, a proprietary B2B e-commerce platform to streamline biological assay services. 

Looking ahead, Syngene expects FY26 revenue growth in the early teens on an underlying basis, with reported growth likely in the mid-single digits due to client-level inventory balancing. EBITDA margins are expected to moderate to the mid-twenties due to costs from the new US facility. The Board has recommended a final dividend of Rs 1.25 per share for FY25. 

(BSE)     

Syngene International reported a strong performance in Q4 FY25 with revenue from operations rising 11% year-on-year to Rs 10.18 billion, crossing the Rs 10 billion mark for the first time. The quarter also saw sequential revenue growth of 8%, supported by robust performance across research, development, and manufacturing services. Operating EBITDA grew 9% YoY, with a margin of 35%, while profit after tax stood at Rs 1.83 billion. For the full fiscal year, revenue from operations rose 4% to Rs 36.42 billion. However, profit after tax before exceptional items declined 8% to Rs 4.75 billion, impacted by sectoral headwinds in the first half. Adjusted for one-offs, full-year PAT remained flat with 1% YoY growth. EBITDA margin for the year moderated to 29%. Key highlights included the acquisition of a biologics manufacturing site in Baltimore, USA, enhancing Syngene’s single-use bioreactor capacity to 50KL and expanding its footprint in the US biologics CDMO market. The company also launched SYNe-MAP™, a proprietary B2B e-commerce platform to streamline biological assay services. Looking ahead, Syngene expects FY26 revenue growth in the early teens on an underlying basis, with reported growth likely in the mid-single digits due to client-level inventory balancing. EBITDA margins are expected to moderate to the mid-twenties due to costs from the new US facility. The Board has recommended a final dividend of Rs 1.25 per share for FY25. (BSE)     

Next Story
Infrastructure Urban

Infrastructure Opportunity Outlook by IMPACCT.Info

India’s infrastructure pipeline is witnessing dynamic activity across stages — from immediate bidding to future planning. IMPACCT segments these into three categories: Immediate, 3–6 Month, and Future Opportunities, enabling businesses to identify, prepare, and participate in high-value tenders and projects across sectors.To read the full article Click Here..

Next Story
Infrastructure Transport

The Road Ahead Begins Here

The future of India’s roads took centrestage at RAHSTA Expo 2026, where policymakers, contractors and industry leaders came together under one roof. The event blended thought leadership, technology showcase and industry recognition into a single powerful platform.India’s roads and highways community gathered in full strength at the Jio World Convention Centre, Mumbai, on July 8-9, 2026, for the 16th edition of the RAHSTA Expo (Roads and Highways Sustainable Technologies & Advancement). Over two action-packed days, the event brought together policymakers, contractors, consultants, devel..

Next Story
Infrastructure Urban

Wricks® is 50 per cent stronger than conventional bricks

India’s construction boom is colliding with mounting plastic and demolition waste. Angirus is responding with Wricks®, made from recycled waste and already deployed in over 400,000 units nationwide. Kunjpreet Arora, Cofounder and CEO, explains the technology, impact and growth roadmap.With several alternative building materials available, what industry gap did Angirus identify and how does Wricks® address it?The construction industry already has alternatives such as AAC blocks, fly-ash bricks and concrete blocks but these have limitations. AAC blocks may crack due to contraction and expans..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

Advertisement

Advertisement